These trials showed clinically important pharmacokinetic interactions [seven] characterised by a reduce during the clearance in the anticancer drug and for this reason elevated exposure. The interpretation of subsequent section II and III clinical trials was complicated since it was not possible to administer precisely the same dose of chemotherapy… Read More